Has Martin Gorrochategui Rodriguez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,007 in general payments to Martin Gorrochategui Rodriguez, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Martin Gorrochategui Rodriguez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Martin Gorrochategui Rodriguez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Martin Gorrochategui Rodriguez, MD

Nephrology · Rio Piedras, PRNPI 1134226574

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,607 of the $3,007 with a category attached, or 86.7%. 11 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 45.5% of the total. Reporting peaked in 2024 at $899 and has fallen 82.7% since, to $155 in 2025.

$3,007in general payments, 2019–2025

Across 32 payments — averaging $93.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bard Peripheral Vascular, Inc.$1K
GSK$315
Calliditas Therapeutics US Inc.$257
Otsuka America Pharmaceutical, Inc.$244
Mallinckrodt Hospital Products Inc.$171
AstraZeneca$171
plus $481 from 5 others

What the payments were for

Speaking & faculty fees$40013%
Food & beverage$2,60787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bard Peripheral Vascular, Inc.	13	$1,369
GSK	4	$315
Calliditas Therapeutics US Inc.	2	$257
Otsuka America Pharmaceutical, Inc.	2	$244
Mallinckrodt Hospital Products Inc.	2	$171
AstraZeneca	2	$171
Bard Access Systems, Inc.	1	$166
Vertex	1	$125
Travere Therapeutics, Inc.	1	$108
Medtronic	3	$61
BD	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,007 in reported general payments places this provider in the 70th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$53,732

Medicare patients

Services billed

804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fentanyl CitrateFentanyl Citrate/Pf	17	$59

Paid to pharmacies, not to this prescriber.

Other nephrology in Rio Piedras

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →